Abstract P3-02-06: A phase II study of 68Ga-ABY-025 PET for non-invasive quantification of HER2 expression in breast cancer
Ali Alhuseinalkhudhur(Uppsala University), Jens Christian Hedemann Sørensen(Uppsala University), Fredrik Y. Frejd(Uppsala University), Henrik Lindman(Uppsala University), Tora Sundin(Uppsala University Hospital), Mark Lubberink(Uppsala University), Per Liss(Uppsala University), Irina Velikyan(Uppsala University), Victor Vishwanath Iyer(Uppsala University), Johan Hartman(Karolinska University Hospital)
Cited by 1
Related Papers
Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment
|PLoS ONE|2009|504
Artificial intelligence as the next step towards precision pathology
|Journal of Internal Medicine|2020|443
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial
|The Lancet|2000|343
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [<sup>68</sup>Ga]ABY-025 Affibody PET/CT
|Theranostics|2015|269
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the <sup>111</sup>In-ABY-025 Affibody Molecule
|Journal of Nuclear Medicine|2014|260